July 4, 2013 -- Luitpold Animal Health, a division of Luitpold Pharmaceuticals, Inc., manufacturers of Adequan IM, Adequan IA, and Adequan Canine, provide the following supply interruption update:
Luitpold’s New York facility has undergone significant renovations and upgrades to meet enhanced quality standards and address observations made by the U.S. Food and Drug Administration (FDA). These renovations required cessation of manufacturing and affected Luitpold’s ability to release product. This has resulted in shortages in the marketplace. Luitpold has worked in recent months to optimally allocate inventory and manage the limited remaining supply, which has now been depleted.
Luitpold remains committed to resuming its manufacture and release of Adequan products. We understand how critically important the Adequan brands are to the health and well-being of the animals receiving treatment. The company’s latest expectations for reestablishing Adequan supply to the market is estimated to be first quarter 2014, however, this hinges upon completion of a successful inspection by the FDA.
The company has established a dedicated webpage on www.adequan.com, where concerned parties can register to receive future communications and updates on this matter. You may also contact our Customer Service Department at 1-800-458-0163.
During this supply interruption, we strongly recommend veterinarians work together with equine and canine owners and caregivers to evaluate and decide upon the safest and most effective alternative treatments.
Adequan IM and IA are the only polysulfated glycosaminoglycans (PSGAGs) approved by the FDA for the treatment of non-infectious degenerative and/or traumatic joint dysfunction and associated lameness in horses. Adequan Canine is the only polysulfated glycosaminoglycan (PSGAG) approved by the FDA for the control of signs associated with non-infectious degenerative and/or traumatic arthritis of canine synovial joints.